LAVA Therapeutics, participated by Ysios Capital, announces pricing of Initial Public Offering
26/03/2021 Press release LAVA THERAPEUTICS ANNOUNCES PRICING OF INITIAL PUBLIC OFFERING. UTRECHT, The Netherlands and PHILADELPHIA, March 24, 2021 (GLOBE NEWSWIRE) — LAVA Therapeutics B.V. (Nasdaq: LVTX), a biotechnology company focused on applying its expertise in bispecific gamma-delta T cell engagers to transform cancer therapy, today announced the pricing of…